Active Biotech AB Interim Report January - September 2013

November 7, 2013 08:35 (CET)

LUND, Sweden, Nov. 7, 2013 (GLOBE NEWSWIRE) --

Laquinimod
  * Analysis of data from the Phase III ALLEGRO study shows that laquinimod
    provides a beneficial impact on brain tissue damage; Laquinimod-treated
    patients accumulated significantly less brain tissue damage caused by
    neurodegeneration
  * New data presented at ECTRIMS shows that laquinimod has an effect on both
    inflammation and the underlying mechanisms associated with disease
    progression in multiple sclerosis
  * Teva is planning to commence clinical trials in Huntington's disease and
    primary progressive multiple sclerosis (PPMS)
  * Teva will initiate a further clinical trial in multiple sclerosis
    (LIBRETTO)

Tasquinimod
  * Phase III 10TASQ10 study is proceeding as planned; the primary analysis of
    progression-free survival (PFS) and survival (OS) is expected in 2014
  * Active Biotech received a milestone payment of EUR 12 M from
    Ipsen

ANYARA
  * Detailed analysis provides further support for ANYARA's efficacy in a
    biomarker-defined sub-group of renal cell cancer patients; the result from
    the Phase II/III study was presented at the 2013 European Cancer Congress

Paquinimod (57-57)
  * Evaluation under way of clinical trial in systemic sclerosis


ISI
  * Project proceeding according to plan


Financial summary

 SEK M                                    Q3                                Jan
                                                Jan - Sept           - Dec

                    2013                2012     2013         2012         2012
-------------------------------------------------------------------------------


 Net sales         107.0                39.8    111.9        136.4        227.9



 Operating loss     27.9               -48.2   -128.6       -168.7       -163.2



 Profit/Loss        29.2               -51.6   -130.0       -175.1       -175.0
 after tax



 Profit/loss per    0.39               -0.75    -1.77        -2.54        -2.54
 share



For further information, please contact:
Tomas Leanderson, President and CEO
Tel: +46 (0)46-19 20 95

Hans Kolam, CFO
Tel: +46 (0)46-19 20 44

Active Biotech AB(Corp. Reg. No. 556223-9227)
Box 724, 220 07 Lund
Tel: +46 (0)46-19 20 00
Fax +46 (0)46-19 11 00

The report is also available at www.activebiotech.com


Active Biotech AB Interim Report January – September 2013 : http://hugin.info/1002/R/1741192/584931.pdf

[HUG#1741192]